The Risk and Impact of COVID-19 Pandemic on Immunosuppressed Patients: Cancer, HIV, and Solid Organ Transplant Recipients

Aids Reviews ◽  
2020 ◽  
Vol 22 (3) ◽  
Author(s):  
Ali Haider Mohammed ◽  
Ali Blebil ◽  
Juman Dujaili ◽  
Bassam A. Rasool-Hassan
Keyword(s):  
Organ Transplant ◽  
Solid Organ Transplant ◽  
Solid Organ ◽  
Transplant Recipients ◽  
Organ Transplant Recipients ◽  
Immunosuppressed Patients ◽  
Solid Organ Transplant Recipients

scholarly journals SARS-CoV-2 serologic immune response in exogenously immunosuppressed patients

2020 ◽  
Author(s):  
Megan L Zilla ◽  
Christian Keetch ◽  
Gretchen Mitchell ◽  
Jeffery McBreen ◽  
Michael R Shurin ◽  
...  
Keyword(s):  
Immune Response ◽  
Antibody Response ◽  
Organ Transplant ◽  
Solid Organ Transplant ◽  
Organ Transplant Recipient ◽  
Solid Organ ◽  
Transplant Recipients ◽  
Organ Transplant Recipients ◽  
Immunosuppressed Patients ◽  
Solid Organ Transplant Recipients

Abstract Background While it is presumed that immunosuppressed patients, such as solid organ transplant recipients on immunosuppression, are at greater risk from SARS-CoV-2 infection than the general population, the antibody response to infection in this patient population has not been studied. Methods In this report, we follow the anti-SARS-CoV-2 antibody levels in patients with COVID-19 who are undergoing exogenous immunosuppression. Specifically, we studied the antibody response of three solid organ transplant recipient patients, three patients who take daily inhaled fluticasone, and a patient on etanercept and daily inhaled fluticasone, and compared them to five patients not on exogenous immunosuppression. Results We found that the solid organ transplant patients on full immunosuppression are at risk of having a delayed antibody response and poor outcome. We did not find evidence that inhaled steroids nor etanercept predispose patients to delayed immune response to SARS-CoV-2. Conclusion The data presented here suggest that solid organ transplant recipients may be good candidates for early targeted intervention against SARS-CoV-2.

Low-Dose Acitretin for Secondary Prevention of Keratinocyte Carcinomas in Solid-Organ Transplant Recipients

Dermatology ◽  
2021 ◽  
pp. 1-6
Author(s):  
Efrat Solomon-Cohen ◽  
Shiran Reiss-Huss ◽  
Emmilia Hodak ◽  
Batya Davidovici
Keyword(s):  
Secondary Prevention ◽  
Cell Carcinoma ◽  
Low Dose ◽  
Organ Transplant ◽  
Solid Organ Transplant ◽  
Solid Organ ◽  
Transplant Recipients ◽  
Organ Transplant Recipients ◽  
Pretreatment Period ◽  
Solid Organ Transplant Recipients

<b><i>Background:</i></b> Keratinocyte carcinomas, particularly squamous cell carcinoma (SCC), occur more frequently and aggressively in solid-organ transplant recipients (SOTRs) than in the general population. Systemic retinoids are effective in secondary prevention of keratinocyte carcinomas in this population, but their use is limited by adverse effects including a rebound effect in cases of treatment discontinuation. <b><i>Objective:</i></b> Our aim was to determine whether low-dose acitretin is efficient in the secondary prevention of keratinocyte carcinomas in SOTRs. <b><i>Methods:</i></b> This retrospective case-crossover study was conducted at a specialized dermatology clinic for SOTRs in a large transplantation center in 2010–2017. Patients with at least 1 previous keratinocyte carcinoma who were treated with acitretin 10 mg/day for 2 years were included. The main outcome was the difference in the number of new keratinocyte carcinomas diagnosed during treatment compared to during the 2-year pretreatment period. <b><i>Results:</i></b> The cohort included 34 SOTRs. A significant reduction in the mean number of new keratinocyte carcinomas during treatment relative to the pretreatment period was observed (1.7 vs. 3.6, –53% <i>p</i> = 0.002). Similar results were noted on analysis by tumor type, for both SCC and basal cell carcinoma. <b><i>Conclusion:</i></b> This study of SOTRs demonstrated positive results for low-dose acitretin as a chemoprevention of keratinocyte carcinomas in this population.

scholarly journals COVID‐19 in solid organ transplant recipients: A national cohort study from Sweden

2021 ◽  
Author(s):  
John Mackay Søfteland ◽  
Gustav Friman ◽  
Bengt von Zur‐Mühlen ◽  
Bo‐Göran Ericzon ◽  
Carin Wallquist ◽  
...  
Keyword(s):  
Cohort Study ◽  
Organ Transplant ◽  
Solid Organ Transplant ◽  
Solid Organ ◽  
Transplant Recipients ◽  
Organ Transplant Recipients ◽  
National Cohort ◽  
Solid Organ Transplant Recipients
Sign in / Sign up

Export Citation Format

Share Document